HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
3-Week radiation blast could spare seniors from 7 weeks of treatment
Disease control CompletedThis study tested a shorter radiation schedule (3 weeks instead of 6-7) for head and neck cancer in people aged 70 and older. The goal was to see if it could still control the cancer while reducing side effects and treatment gaps. 37 participants received either adjuvant or defin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo injection shows promise for tough head and neck cancers
Disease control CompletedThis study tested a new drug (MK-1454) injected directly into tumors, combined with the immunotherapy pembrolizumab, for people with advanced head and neck cancer that had not been treated before. The goal was to see if the combination worked better than pembrolizumab alone. 18 a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo aims to boost immune system against Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Scientists hunt for clues to predict who benefits from head and neck cancer drug
Knowledge-focused CompletedThis completed study looked at 50 people with advanced head and neck cancer that had stopped responding to chemotherapy. Researchers gave them the drug nivolumab and analyzed their tumors and blood to find biological markers that could predict who would respond best. The goal was…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Yonsei University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC